The BH3-only protein Noxa is stimulated during apoptosis of chronic lymphocytic leukemia cells triggered by M2YN, new plant-derived extract

International Journal of Oncology

Volumn 39, Issue 4, 2011, Pages 965-972

  Zaher, Murhaf ^a,b,c   Mirshahi, Massoud ^a,b,c,d   Nuraliev, Yusuf ^e   Sharifova, Mijgana ^e   Bombarda, Isabelle ^f   Marie, Jean Pierre ^a,b,c,g   Billard, Christian ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Academy of Sciences of the Republic of Tadzhikistan   (Tajikistan)

^e International Institute for Avicenna Heritage and Pharmacology   (Tajikistan)

^f CNRS   (France)

^g HÔPITAL SAINT ANTOINE   (France)

Author keywords

Apoptosis induction; Bcl 2 family; CLL; M2Yn; Noxa upregulation

Indexed keywords

BH3 PROTEIN; CASPASE 3; FLAVOPIRIDOL; HYPERFORIN; M2YN EXTRACT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHATIDYLSERINE; PLANT EXTRACT; PROTEASOME; PROTEIN BAK; PROTEIN MCL 1; PROTEIN NOXA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN TARGETING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; CASPASE 3; DNA FRAGMENTATION; FEMALE; FLAVONOIDS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MIDDLE AGED; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; PHLOROGLUCINOL; PHOSPHATIDYLSERINES; PIPERIDINES; PLANT EXTRACTS; POLY(ADP-RIBOSE) POLYMERASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; TERPENES; TUMOR CELLS, CULTURED;

EID: 79960857713     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1121     Document Type: Article

References (45)

1. Ghia P, Ferreri AJM, and Caligaris-Cappio F: Chronic lymphocytic leukemia. Crit Rev Oncol Hematol 64: 234-246, 2007. (Pubitemid 350026781)
2. Pleyer L, Egle A, Hartmann TN and Greil R: Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 6: 405-418, 2009.
3. Tam CS and Keating MJ: Chemoimmunotherapy of chronic lymphocytic leukemia. Nat Rev Clin Oncol 7: 521-532, 2010.
4. Kolb JP, Kern C, Quiney C, Roman V and Billard C: Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Hematol Disord 3: 261-286, 2003. (Pubitemid 37540859)
5. Byrd JC, Shinn C, Waselenko JK, et al: Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 92: 3804-3816, 1998. (Pubitemid 28525207)
6. Lucas DM, Edwards RB, Lozanski G, et al: The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 113: 4656-4666, 2009.
7. Hahntow IN, Schneller F, Oelsner M, et al: Cyclin-dependent kinases inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia. Leukemia 18: 747-755, 2004. (Pubitemid 38500193)
8. Balakrishnan K, Wierda WG, Keating MJ and Gandhi V: Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 112: 1971-1980, 2008.
9. Roman V, Billard C, Kern C, et al: Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia. Br J Haematol 117: 1-10, 2002.
10. Billard C, Menasria F, Quiney C, Faussat, AM, Finet JP, Combes S and Kolb JP: 4-arylcoumarin analogues of combretastatins stimulate the apoptosis of leukemic cells from chronic lymphocytic leukemia patients. Exp Hematol 36: 1625-1633, 2008.
11. Quiney C, Billard C, Faussat AM, et al: Pro-apoptotic properties of hyperforin in leukemic cells from patients with chronic lymphocytic leukemia. Leukemia 20: 491-497, 2006. (Pubitemid 43291749)
12. Kitada S, Zapata JM, Andreeff M and Reed JC: Protein kinase inhibitor flavopiridol and 7-hydroxystaurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96: 393-397, 2000. (Pubitemid 30463354)
13. Chen R, Keating MJ, Gandhi V and Plunkett W: Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106: 2513-2519, 2005. (Pubitemid 41510827)
14. Gandhi V, Balakrishnan K and Chen LS: Mcl-1: the 1 in CLL. Blood 112: 3538-3540, 2008.
15. Zaher M, Akrout I, Mirshahi M, Kolb JP and Billard C: Noxa upregulation is associated with apoptosis of chronic lymphocytic leukemia cells induced by hyperforin but not flavopiridol. Leukemia 23: 594-596, 2009.
16. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM and Huang DCS: Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294-1305, 2005. (Pubitemid 41003019)
17. Qin JZ, Ziffra J, Stennett L, et al: Proteasome inhibitors trigger Noxa-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65: 6282-6293, 2005. (Pubitemid 40994414)
18. Inoue S, Riley J Gant TW, Dyer MJS and Cohen GM: Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 21: 1773-1782, 2007. (Pubitemid 47086766)
19. Flinn IW, Byrd JC, Bartlett N, et al: Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 29: 1253-1257, 2005. (Pubitemid 41297636)
20. Faderl S, Rai K, Gribben J, et al: Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 107: 916-924, 2006. (Pubitemid 44291139)
21. Byrd JC, Marcucci G, Parthum MR, et al: A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105: 959-967, 2005. (Pubitemid 40170861)
22. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 111: 5446-5456, 2008.
23. kip1 in malignant cells from B-cell chronic lymphocytic leukemia. Leukemia 17: 2345-2443, 2003.
24. Fourneron JD and Naït-Si Y: Effect of eluent pH on HPLC/UV analysis of hyperforin. Phytochem Anal 17: 71-77, 2006.
25. Kern C, Cornuel J, Billard C, et al: Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103: 679-688, 2004. (Pubitemid 38145555)
26. Moravec RA, O'Brien MA, Daily WJ, Scurria MA, Bernad L and Riss TL: Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format. Anal Biochem 387: 294-302, 2009.
27. Dai Y, De Sano J, Tang W, et al: Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PLoS One 5: e14153, 2010.
28. Chen D, Daniel KG, Chen MS, Kuhn DJ, Landis-Piwowar KR and Ping Dou Q: Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem Pharmacol 69: 1421-1432, 2005. (Pubitemid 40602442)
29. Packham G and Stevenson FK: Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukemia. Immunology 114: 441-449, 2005. (Pubitemid 40478137)
30. Awan FT, Kay NE, Davies ME, et al: Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphomide, and rituximab. Blood 133: 535-537, 2009.
31. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, Lucas DM and Byrd JC: Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: Downregulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res 13: 144-150, 2007.
32. Smit L, Hallaert DYH, Spijker R, et al: Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 109: 1660-1668, 2007. (Pubitemid 46242110)
33. Blagoskonny MV: Flavopiridol, an inhibitor of transcription. Implications, problems ans solutions. Cell Cycle 3: 1537-1542, 2004.
34. Nencioni A, Hua F, Dillon CP, et al: Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood 105: 3255-3262, 2005.
35. Qin JZ, Xin H, Sitailo LA, Denning MF and Nickoloff BJ: Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res 66: 9636-9645, 2006. (Pubitemid 44623663)
36. Kress CL, Konopleva M, Martinez-Garcia V, et al: Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma. PLos One 2: e559, 2007.
37. Shankar S, Singh G and Srivastava RK: Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosc 1: 4839-4854, 2007.
38. Yu F, Watts RN, Zhang XD, Borrow JM and Hersey P: Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent Phenoxodiol-induced apoptosis of human melanoma cells. Anticancer Drugs 17: 1151-1161, 2006. (Pubitemid 44673395)
39. Aiyar SE, Park H, Aldo PB, et al: TMS, a chemically modified herbal derivative of Resveratrol, induces cell death by targeting Bax. Breast Cancer Res Treat 124: 265-277, 2010.
40. Hsu YL, Kuo PL and Lin CC: Isoliquiritigenin induces apoptosis and cell cycle arrest through p53-dependent pathway in Hep G2 cells. Life Sci 3: 279-292, 2005.
41. Rothley M, Schmid A, Thiele W, et al: Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo. Int J Cancer 125: 32-42, 2009.
42. Van Delft MF, Wei AH, Mason KD, et al: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10: 389-399, 2006. (Pubitemid 44711953)
43. Nguyen M, Marcellus RC, Roulston A, et al: Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 104: 19512-19517, 2007.
44. Ghiotto F, Fais F, Tenca C, et al: Apoptosis of B-cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimetic. Cancer Biol Ther 8: 263-271, 2009.
45. O'Brien SM, Claxton DF, Crump M, et al: Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113: 299-305, 2009.